ADMA Biologics (ADMA) Tops Q3 EPS by 2c

ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of $0.15, $0.02 better than the analyst estimate of $0.13. Revenue for the quarter came in at $119.8 million versus the consensus estimate of $105.96 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• Important Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); Insulet Corporation (NASDAQ: PODD); Intuit Inc. (INTU); and Power Solutions International, Inc. (NASDAQ: PSIX): Graba
• DBV Technologies (DBVT) Misses Q2 EPS by 12c
• F.N.B. Corp (FNB) Reports In-Line Q2 EPS